Venture Life Group (VLG) Trading Update summary

Divestment and financial position

• Completed sale of contract development and manufacturing operations and select non-core products, with regulatory approvals secured in Italy and Sweden.

• Net cash position stands at approximately £36 million, enabling pursuit of earnings-enhancing M&A opportunities.

Trading update and outlook

• Ongoing business delivered H1 2025 revenues of £15.3 million, up 38% year-on-year; proforma growth was 11%.

• Health & Her/Him brands contributed £3.4 million, a 21% proforma increase over the prior year.

• Increased marketing investment and new product listings expected to drive further revenue growth in H2.

• Order book visibility and new listings support confidence in meeting full-year market expectations.

Management appointments and strategic focus

• Kate Bache appointed Chief Marketing and Innovation Officer, joining the Board in November 2025.

• Gervase Fernandes named Strategic Growth Director, focusing on global retail partnerships.

• Sarah Arthur becomes Interim Commercial Director, bringing extensive Johnson & Johnson experience.

• Matt Jeffs appointed Head of M&A to support acquisition strategy.

• Leadership changes aim to drive organic and acquired growth under a capital-light, brand-focused strategy.